Abstract
Angiotensin II type 1 receptor antagonists (AT1R blockers, or ARBs) are used commonly in the treatment of cardiovascular disorders such as heart failure and hypertension. Their clinical success arises from their ability to prevent deleterious Gαq protein activation downstream of AT1R, which leads to a decrease in morbidity and mortality. Recent studies have identified AT1R ligands that concurrently inhibit Gαq protein-dependent signaling and activate Gαq proteinindependent/ β-arrestin-dependent signaling downstream of AT1R, events that may actually improve cardiovascular performance more than conventional ARBs. The ability of such ligands to induce intracellular signaling events in an AT1R-β-arrestin-dependent manner while preventing AT1R-Gαq protein activity defines them as biased AT1R ligands. This mini-review will highlight recent studies that have defined biased signaling at the AT1R and discuss the possible clinical relevance of β-arrestin-biased AT1R ligands in the cardiovascular system.
Keywords: apoptosis, AT1R, β-arrestin, biased signaling, contractility, hypertrophy, internalization, transactivation, antagonists, cardiovascular disorders, hypertension, morbidity, mortality, cardiomyocytes, endocytosis
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor
Volume: 11 Issue: 2
Author(s): Douglas G. Tilley
Affiliation:
Keywords: apoptosis, AT1R, β-arrestin, biased signaling, contractility, hypertrophy, internalization, transactivation, antagonists, cardiovascular disorders, hypertension, morbidity, mortality, cardiomyocytes, endocytosis
Abstract: Angiotensin II type 1 receptor antagonists (AT1R blockers, or ARBs) are used commonly in the treatment of cardiovascular disorders such as heart failure and hypertension. Their clinical success arises from their ability to prevent deleterious Gαq protein activation downstream of AT1R, which leads to a decrease in morbidity and mortality. Recent studies have identified AT1R ligands that concurrently inhibit Gαq protein-dependent signaling and activate Gαq proteinindependent/ β-arrestin-dependent signaling downstream of AT1R, events that may actually improve cardiovascular performance more than conventional ARBs. The ability of such ligands to induce intracellular signaling events in an AT1R-β-arrestin-dependent manner while preventing AT1R-Gαq protein activity defines them as biased AT1R ligands. This mini-review will highlight recent studies that have defined biased signaling at the AT1R and discuss the possible clinical relevance of β-arrestin-biased AT1R ligands in the cardiovascular system.
Export Options
About this article
Cite this article as:
G. Tilley Douglas, Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187153011795564133
DOI https://dx.doi.org/10.2174/187153011795564133 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring the Technology Landscape of 7TMR Drug Signaling Profiling
Current Topics in Medicinal Chemistry Cell-penetrating Peptides as Nucleic Acid Delivery Systems: From Biophysics to Biological Applications
Current Pharmaceutical Design Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets miRNA-Dependent Activation of mRNA Translation
MicroRNA Beta-Blockers use for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Roles of Renal Proximal Tubule Transport in the Pathogenesis of Hypertension
Current Hypertension Reviews The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets The Links Between Sleep Apnea and Chronic Kidney Disease
Current Respiratory Medicine Reviews Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Oxidative Stress in the Pathogenesis/Treatment of Atherosclerosis
Current Nutrition & Food Science Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes
Current Drug Targets Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews The Road to Device Miniaturization in Echocardiography
Recent Patents on Medical Imaging Intrahepatic Cholestasis of Pregnancy and Bile Acids Induced Lung Injury in Newborn Infants
Current Pediatric Reviews Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology Fish Oil Fatty Acids as Cardiovascular Drugs
Current Vascular Pharmacology